Sinopharm Group Co Ltd (1099.HK) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN CNE100000FN7
Sinopharm Group Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 584.54 bn CNY | 576.90 bn CNY |
| Gross profit | 44.26 bn CNY | 41.80 bn CNY |
| EBIT | 16.19 bn CNY | 16.09 bn CNY |
| Net income | 7.05 bn CNY | 7.18 bn CNY |
| Diluted EPS – continuing operations | 2.26 CNY | 2.30 CNY |
Full history since 2006, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sinopharm Group Co Ltd
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices Distribution segment distributes medical devices, as well as provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the distribution of laboratory supplies; manufacture and distribution of chemical reagents; and production and sale of pharmaceutical products. The company rents and manages properties; distributes medical instruments and equipment, Chinese herbal medicines, antibiotics, and biological products; and offers information technology, investment, goods and technology import and export, business consulting, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. It also manages medical project investment, consulting, and technology training activities; and manufactures medicines. Sinopharm Group Co. Ltd. was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
More stocks
- OPEN TEXT CORP (OTEX)
- Shenzhen New Industries Biomedical (300832.SZ)
- Fiberhome Telecommunication Technologies Co Ltd (600498.SS)
- JD Sports Fashion PLC (JD.L)
- Valaris Ltd (VAL)
- Aura Minerals Inc (ORA.TO)
- Ypsomed Holding AG (YPSN.SW)
- Bank of East Asia Ltd (23.HK)
- Gan & Lee Pharmaceuticals Co Ltd (603087.SS)
- Triple Flag Precious Metals Corp (TFPM.TO)
- Technip Energies NV (TE.PA)
- Autotrader Group PLC (AUTO.L)
Not investment advice. All data without warranty, price as of 20.10.2026. Details in the risk notice.